[go: up one dir, main page]

MX2013008729A - Metodos y composiciones para tratar, reducir, o prevenir el deterioro del sistema visual de los animales. - Google Patents

Metodos y composiciones para tratar, reducir, o prevenir el deterioro del sistema visual de los animales.

Info

Publication number
MX2013008729A
MX2013008729A MX2013008729A MX2013008729A MX2013008729A MX 2013008729 A MX2013008729 A MX 2013008729A MX 2013008729 A MX2013008729 A MX 2013008729A MX 2013008729 A MX2013008729 A MX 2013008729A MX 2013008729 A MX2013008729 A MX 2013008729A
Authority
MX
Mexico
Prior art keywords
methods
compositions
visual system
treating
reducing
Prior art date
Application number
MX2013008729A
Other languages
English (en)
Other versions
MX348898B (es
Inventor
Yuanlong Pan
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2013008729A publication Critical patent/MX2013008729A/es
Publication of MX348898B publication Critical patent/MX348898B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Se divulgan métodos y composiciones para tratar, reducir o prevenir el deterioro de al menos un componente del sistema visual de un animal. Los métodos comprenden administrar al animal una composición que comprende AGI y CLON en una cantidad eficaz para tratar, reducir o prevenir el deterioro de al menos un componente del sistema visual. También se describen los métodos para prolongar los años de plenitud de la vida de un animal, mejorar la calidad de vida y fomentar la salud y el bienestar de un animal, utilizando composiciones que comprenden los AGI y CLON.
MX2013008729A 2011-01-25 2012-01-24 Métodos y composiciones para tratar, reducir, o prevenir el deterioro del sistema visual de los animales. MX348898B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161461913P 2011-01-25 2011-01-25
PCT/US2012/022297 WO2012103049A1 (en) 2011-01-25 2012-01-24 Methods and compositions for treating, reducing or preventing deterioration of the visual system of animals

Publications (2)

Publication Number Publication Date
MX2013008729A true MX2013008729A (es) 2013-08-14
MX348898B MX348898B (es) 2017-07-03

Family

ID=46581129

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008729A MX348898B (es) 2011-01-25 2012-01-24 Métodos y composiciones para tratar, reducir, o prevenir el deterioro del sistema visual de los animales.

Country Status (12)

Country Link
US (1) US9320759B2 (es)
EP (1) EP2667882B1 (es)
JP (1) JP2014504605A (es)
CN (1) CN103442725A (es)
AU (1) AU2012209285B2 (es)
BR (1) BR112013018839A2 (es)
CA (1) CA2825022A1 (es)
ES (1) ES2828479T3 (es)
MX (1) MX348898B (es)
RU (1) RU2597793C2 (es)
WO (1) WO2012103049A1 (es)
ZA (1) ZA201306388B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3082784A1 (en) * 2013-12-19 2016-10-26 F.Hoffmann-La Roche Ag Cetp modulator for use in the treatment of eye disease
RU2667640C1 (ru) * 2013-12-19 2018-09-21 Тассос ГЕОРГИУ Композиции омега-3 жирных кислот для лечения заболеваний, вызывающих поражение нервной системы
JP2017531651A (ja) * 2014-10-10 2017-10-26 ネステク ソシエテ アノニム 移動能力又は動作能力を改善するため、あるいはフレイルを治療するための組成物及び方法
RU2632958C2 (ru) * 2015-10-20 2017-10-11 федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный технический университет им. И.И. Ползунова" (АлтГТУ) Сироп бальзамный для профилактики потери остроты зрения
WO2017109623A1 (en) * 2015-12-22 2017-06-29 Nestec Sa Immune health for companion animals
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CN106689960A (zh) * 2017-01-11 2017-05-24 珠海市御得养生食品研究院有限公司 一种保护视力固体饮料
US10682325B2 (en) 2017-08-14 2020-06-16 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
US11696593B2 (en) 2018-08-24 2023-07-11 Bioscience Formulators, LLC Astaxanthin nutritional compositions and uses
KR102797943B1 (ko) * 2021-06-28 2025-04-18 데일리컬러스 헬스 인크. 염증 및 노화와 관련된 프로세스에 대항하고 세포 에너지 및/또는 대사를 지원하기 위한 조성물 및 방법 (compositions and methods to counteract processes associated with inflammation and senescence and to support cellular energy and/or metabolism)
WO2023183212A1 (en) * 2022-03-22 2023-09-28 Ark Naturals Company Edible soft dental chew and methods of using the same
WO2025151943A1 (pt) * 2024-01-18 2025-07-24 Moro Peres Nemecio Suplemento alimentar particularmente indicado para combate da degeneração macular, cápsula compreendendo o dito suplemento e uso do mesmo

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952033A (en) 1996-12-24 1999-09-14 Nestec S.A. Gelatinized cereal product containing oligosaccharide and processes of preparing and using same
PT862863E (pt) 1997-01-09 2002-04-29 Nestle Sa Produto cerealifero contendo probioticos
ATE397868T1 (de) 1999-09-07 2008-07-15 Nestle Sa Verfahren zur verbesserung der haut und des pelzes von haustieren
RU2254772C2 (ru) 1999-09-22 2005-06-27 Сосьете Де Продюи Нестле С.А. Способ повышения активности стареющего домашнего животного
EA006428B1 (ru) 2000-05-25 2005-12-29 Сосьете Де Продюи Нестле С.А. Штаммы молочно-кислых бактерий и их применение
EP1296565B1 (en) 2000-05-26 2006-08-23 Societe Des Produits Nestle S.A. Foodstuff for pets
GB0027761D0 (en) 2000-11-14 2000-12-27 Nestle Sa Nutritional composition for an immune condition
EP1344458A1 (en) 2002-03-12 2003-09-17 Société des Produits Nestlé S.A. Probiotic delivery system
WO2005110375A1 (en) 2004-05-08 2005-11-24 Paul Edward L Jr Nutritional supplement for treatment of ocular diseases
US20060046982A1 (en) * 2004-08-26 2006-03-02 Waugh William H Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease
US20060088574A1 (en) * 2004-10-25 2006-04-27 Manning Paul B Nutritional supplements
RU2400102C2 (ru) * 2005-08-26 2010-09-27 Нестек С.А. Композиция для лечения, замедления или предотвращения у животного слабоумия, старения мозга, когнитивного нарушения, инсульта или болезни альцгеймера и ее применение (варианты)
BRPI0617175A2 (pt) 2005-09-30 2011-07-12 Nestec Sa composições, bem como uso de ácidos graxos poli-insaturados de cadeia longa (lcpufa) na preparação das mesmas, para melhora da função cognitiva
WO2008143642A2 (en) 2006-11-09 2008-11-27 Children's Medical Center Corporation Methods of treating and preventing ocular neovascularization with omega-3 polyunsaturated fatty acids
JP5931337B2 (ja) * 2007-10-04 2016-06-08 ネステク ソシエテ アノニム 認知機能を高める組成物及び方法
US20090110674A1 (en) * 2007-10-24 2009-04-30 Loizou Nicos C Health supplement
US20090192226A1 (en) * 2007-12-17 2009-07-30 Josef Neu Materials and Methods for Treatment of Pathological Ocular Vascular Proliferation
EP2224930B1 (en) * 2008-01-04 2016-06-15 Nestec S.A. Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing congnitive and related functions
US20090325999A1 (en) 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
WO2010074940A1 (en) 2008-12-23 2010-07-01 Alcon Research, Ltd. Compositions and nutritional supplements for improving ocular health and reducing ocular inflammatory response
EP2429317B2 (en) * 2009-04-17 2019-02-20 Natac Pharma, S.L. Compositions rich in omega-3 fatty acids with a low content in phytanic acid
US20110208153A1 (en) * 2010-02-24 2011-08-25 John Alvey Formulations and methods for nutrient delivery

Also Published As

Publication number Publication date
EP2667882A1 (en) 2013-12-04
ES2828479T3 (es) 2021-05-26
CN103442725A (zh) 2013-12-11
WO2012103049A1 (en) 2012-08-02
JP2014504605A (ja) 2014-02-24
EP2667882B1 (en) 2020-08-12
AU2012209285A1 (en) 2013-08-01
CA2825022A1 (en) 2012-08-02
US20130309329A1 (en) 2013-11-21
EP2667882A4 (en) 2014-06-25
AU2012209285B2 (en) 2016-11-17
BR112013018839A2 (pt) 2016-09-27
ZA201306388B (en) 2015-03-25
US9320759B2 (en) 2016-04-26
RU2597793C2 (ru) 2016-09-20
MX348898B (es) 2017-07-03
RU2013139430A (ru) 2015-03-10

Similar Documents

Publication Publication Date Title
MX2013008729A (es) Metodos y composiciones para tratar, reducir, o prevenir el deterioro del sistema visual de los animales.
WO2012112340A3 (en) Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
MX2009011898A (es) Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido.
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
BR112012021905A2 (pt) tratamento de nefrite lúpica usando laquinimod
MY177331A (en) Improved antagonist antibodies against gdf-8 and uses therefor
MX351670B (es) Bacteria bacillus para uso en tratar y prevenir infecciones en animales acuaticos.
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
PH12014500767A1 (en) Compositions for the treatment of dry eye
MY150602A (en) Subtituted-quinoxaline-type piperidine compounds and the uses thereof
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
NZ602478A (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
MX363465B (es) Tratamiento de la grasa submental.
NZ597031A (en) Perhexiline for use in the treatment of hypertrophic cardiomyopathy (hcm)
DK2714888T3 (da) Rekombinant gær
PH12012500773A1 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
AU2016216741A1 (en) Compositions and methods of use of an inappetance-controlling compound
ATE538799T1 (de) Zusammensetzungen zur behandlung von haarverlust
MX2011012310A (es) Tratamiento de insuficiencia cardiaca con fracción de eyeccion normal (icfen).
MX347263B (es) Metodos para incrementar la produccion o actividad de catalasa.
WO2011153377A3 (en) Methods and compositions for treating a subject for central nervous system (cns) injury
MX2013007191A (es) Metodos y composiciones para prevenir y tratar la osteoartritis.
MX2011007885A (es) Formulaciones de emulsion de narcoticos para tratamiento de dolor por cancer.
WO2014026013A3 (en) Methods for maintaining or improving health, well-being and/or a physiological function in a subject

Legal Events

Date Code Title Description
FG Grant or registration